Search results (1331)
« Back to PublicationsTime now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies.
Eyre TA. et al, (2014), Br J Haematol, 166, 336 - 351
Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom.
Rule S. et al, (2014), J Med Econ, 17, 459 - 468
Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo
Woll PS. et al, (2014), Cancer Cell, 25, 794 - 808
Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.
Woll PS. et al, (2014), Cancer Cell, 25, 794 - 808
10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN A SINGLE UK CENTRE: COMPARISON WITH PRE-TKI ERA AND EVALUATION OF 2013 ELN GUIDELINES
Khan D. et al, (2014), HAEMATOLOGICA, 99, 341 - 341
A NATIONAL EXPERIENCE OF THE USE OF PONATINIB IN PATIENTS MULTIPLE TYROSINE KINASE INHIBITORS CONFIRMS EFFICACY IN A HEAVILY PRE-TREATED COHORT OF PATIENTS WITH PH plus LEUKAEMIAS
Milojkovic D. et al, (2014), HAEMATOLOGICA, 99, 335 - 335
FLT3-ITD INDUCED MYELOPROLIFERATION CAUSES A CELL EXTRINSIC DEPLETION OF HAEMATOPOIETIC STEM CELLS
Mead AJ. et al, (2014), HAEMATOLOGICA, 99, 256 - 256
Gemcitabine-induced large vessel vasculitis demonstrated by PET CT: a rare, important side effect.
Eyre TA. et al, (2014), Int J Hematol, 99, 798 - 800
OUTCOMES FOR MYELOFIBROSIS PATIENTS WHO SWITCHED FROM FEDRATINIB TO RUXOLITINIB THERAPY
Garcia NC. et al, (2014), HAEMATOLOGICA, 99, 670 - 671
T-cell/histiocyte-rich large B-cell lymphoma--transformation of nodular lymphocyte predominant Hodgkin lymphoma in the bone marrow.
Eyre TA. et al, (2014), Eur J Haematol, 92, 550 - 551
A decision tree analysis of selective endoscopic ultrasound in staging oesophageal cancer
Findlay JM. et al, (2014), BRITISH JOURNAL OF SURGERY, 101, 18 - 19
Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.
Corrie PG. et al, (2014), Lancet Oncol, 15, 620 - 630
DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.
Gupta A. et al, (2014), Ann Oncol, 25, 968 - 974
Outcomes of adult patients undergoing autologous haematopoietic stem cell transplantation for T cell lymphoma in the Oxford region (1995-2012)
Sims MC. et al, (2014), BRITISH JOURNAL OF HAEMATOLOGY, 165, 101 - 102
Partial engraftment following plerixafor rescue after failed sibling donor peripheral blood stem cell harvest.
Eyre TA. et al, (2014), Transfusion, 54, 1231 - 1234
The utility of restaging PET-CT In predicting progression to unresectable oesophageal cancer after neoadjuvant chemotherapy
Findlay JM. et al, (2014), BRITISH JOURNAL OF SURGERY, 101, 19 - 19
Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanoma.
Sinha R. et al, (2014), Br J Dermatol, 170, 997 - 999
XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: Suitability as a biomarker for patient selection
Hatch SB. et al, (2014), International Journal of Cancer, 134, 1495 - 1503
XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: suitability as a biomarker for patient selection.
Hatch SB. et al, (2014), Int J Cancer, 134, 1495 - 1503
A STUDY OF THE EFFECT OF DABRAFENIB (D) AS AN INDUCER OF CYTOCHROME P450 (CYP) USING WARFARIN (W) AS A PROBE.
Carson SW. et al, (2014), CLINICAL PHARMACOLOGY & THERAPEUTICS, 95, S36 - S36